This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Nasdaq Crosses 15K for 1st Time Ever; JWN, URBN Beat
by Mark Vickery
On the way to its fourth-straight up day in the market, the tech-heavy Nasdaq wound up surpassing 15K for its first time ever.
Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs
by Sweta Jaiswal, FRM
The biotech space has once again come under the spotlight as the FDA has granted the first full U.S. approval to Pfizer (PFE)/BioNTech's (BNTX) coronavirus vaccine.
Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion
by Zacks Equity Research
Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.
Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Medigen announces launch of its COVID-19 vaccine MVC-COV1901 adjuvanted with CpG 1018 of the former.
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News
by Sweta Killa
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
FDA Grants First Full Approval of COVID-19 Vaccine
by Zacks Equity Research
FDA Grants First Full Approval of COVID-19 Vaccine.
Indexes Back At (or Near) All-Time Highs; BBY Beats Estimates
by Mark Vickery
The Nasdaq has registered its first all-time closing high for the first time since August 5th.
Stock Market News for Aug 24, 2021
by Zacks Equity Research
U.S. stock markets rallied on Monday after a disappointing last week.
3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval
by Zacks Equity Research
Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks. JNJ is another strong contender in this field.
Company News for Aug 24, 2021
by Zacks Equity Research
Companies In The News Are: GM, JD, PFE, TRIL, MSGE.
Pfizer (PFE)/BioNTech Comirnaty Gets FDA's Full Approval
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty becomes the first vaccine to be granted full approval by the FDA.
5 Stocks At the Forefront of the Latest S&P 500 Rally
by Sweta Killa
The S&P 500 showed strength to start the new week and hit a new peak on a vaccine boost. This benefited the KR, REGN, TJX, ISRG, MSFT stocks.
Top 5 High-Yielding Stock Market Gainers YTD With More Upside
by Nalak Das
We have narrowed down our search to five large-cap stocks (market capital >$30 billion) that have popped more than 30% year to date. These are: AIG, MET, BX, COP and EOG.
Markets Surge on Pfizer Vax Approval
by Mark Vickery
Led by shares of BioNTech (BNTX), which gained +9.6% on the day, the Nasdaq zoomed ahead to its single-best trading day since May 20th and finished at a brand new all-time high close.
Markets Bounce Back as Slow Summer Weeks Are Here
by Mark Vickery
Fewer than 90 companies are scheduled to release earnings this week, and at first glance none look to represent the S&P 500.
Wall Street Waits For The Fed's Big Event
by Zacks Equity Research
Wall Street Waits For The Fed's Big Event.
Pfizer (PFE) Xeljanz Gets EC Nod for Kids Psoriatic Arthritis
by Zacks Equity Research
With the approval for polyarticular JIA and juvenile PsA, Pfizer's (PFE) Xeljanz is now approved for four indications in Europe.
Biotech ETFs to Benefit From Latest Booster Update
by Sweta Jaiswal, FRM
The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.
Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine is being probed for higher risk of heart inflammation compared to Pfizer's vaccine, per a Washington Post article.
Pharma Stock Roundup: FDA Nod for MRK, PFE Products & New Use of LLY, GSK Drugs
by Kinjel Shah
FDA approves Merck's (MRK) Welireg and Pfizer's (PFE) TICOVAC vaccine and new indications for Lilly's (LLY) Jardiance and Glaxo's (GSK) Jemperli.
US Set to Receive COVID-19 Vaccine Booster Dose Next Month
by Indrajit Bandyopadhyay
In order to provide better protection to the American people from rising COVID-19 cases due to the surge of the Delta variant, U.S. health officials are recommending use of a booster dose for individuals starting this fall.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Delta Variant Catches Up with the Stock Market
by Mark Vickery
Today, worries about growth and demand, at least partially caused by the Delta variant of Covid-19 manifesting in pockets of America.
Pfizer (PFE)/BioNTech Give First COVID Jab Booster Data to FDA
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) booster dose of COVID-19 vaccine elicited antibody levels that were much higher than that seen after the two-dose primary schedule.